Eton sharply raises 2026 outlook and hits long‑term targets early

 

Eton beats Q3 2026 estimates with EPS $0.50 and revenue $57.9M

• Revenue up 158% YoY to $57.9M, driven by first full Hemangiol quarter.
• EPS was $0.50, up 1150% YoY in Q3 2026 quarter.
• Adjusted EBITDA margin reached 49%, essentially achieving 2028 target two years early.
• 2026 revenue guidance raised to >$175M from >$145M; EBITDA margin now >40%.
• All key branded products hit record active patient counts, supporting sustainability of growth.
• Q3 cash from operations was $35M; cash balance a record $55.6M with reduced debt.
• Pipeline strengthened with Libervant, ASN‑001, ET900 and ET700 reformulation plan.
• Libervant targets $450M U.S. seizure‑cluster market with April 2027 launch envisioned.
• ASN‑001 topical hemangioma could surpass Hemangiol economics; NDA planned mid‑2027.
• Preliminary ET700 data show better GI tolerability but weaker copper absorption inhibition versus GALZIN; faster‑release follow‑on planned in 2027.
• Key risk is regulatory and execution timing around Libervant and multiple stacked 2027–2028 rare‑disease launches.
• Strong quarter, driven by Hemangiol‑fueled revenue surge, broad portfolio strength, and dramatic margin expansion.

https://finviz.com/stock?t=ETON&p=d